Curis (NASDAQ:CRIS) Issues Earnings Results, Misses Estimates By $0.92 EPS

Curis (NASDAQ:CRIS) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.92), FiscalAI reports.

Here are the key takeaways from Curis’ conference call:

• Curis said its registrational Take Aim Lymphoma study in PCNSL remains on track, with the company expecting the trial to support accelerated submissions in both the U.S. and Europe after discussions with the FDA and EMA.
• The company plans to begin dosing the first five patients in its Take Aim CLL study by mid-2026, with initial data expected in December and the study designed to test whether emavusertib can deepen responses beyond BTK inhibitor monotherapy.
• Management highlighted early clinical data from the gastroesophageal cancer program, saying results in 16 evaluable patients showed a manageable toxicity profile and encouraging preliminary activity.
• Curis reported a first-quarter 2026 net loss of $24.2 million, wider than the $10.6 million loss a year ago, with the change mainly tied to warrant-liability fair value adjustments from the January PIPE financing.
• The company ended the quarter with $15 million in cash and expects available financing, including potential warrant proceeds, to fund planned operations into the second half of 2027.

Curis Stock Down 9.2%

NASDAQ CRIS opened at $0.50 on Thursday. The stock has a market capitalization of $19.99 million, a PE ratio of -0.42 and a beta of 3.08. The company has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.97. Curis has a 12-month low of $0.49 and a 12-month high of $3.13.

Institutional Trading of Curis

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC lifted its stake in shares of Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after buying an additional 8,973 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Curis in the fourth quarter worth $26,000. Maverick Capital Ltd. lifted its stake in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after buying an additional 65,404 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CRIS shares. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Curis in a research report on Friday, March 20th. Wall Street Zen upgraded shares of Curis to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.00.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.